scholarly journals An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

2012 ◽  
Vol 20 (1) ◽  
pp. 85-94 ◽  
Author(s):  
Ciaran D. Scallan ◽  
Debora W. Tingley ◽  
Jonathan D. Lindbloom ◽  
James S. Toomey ◽  
Sean N. Tucker
Keyword(s):  
Avian Influenza ◽  
Oral Delivery ◽  
Neutralizing Antibodies ◽  
Rapid Development ◽  
Adenovirus Vector ◽  
Oral Route ◽  
Lethal Challenge ◽  
Double Stranded Rna ◽  
Virus Challenge ◽  
H5n1 Avian Influenza

ABSTRACTAn oral gene-based avian influenza vaccine would allow rapid development and simplified distribution, but efficacy has previously been difficult to achieve by the oral route. This study assessed protection against avian influenza virus challenge using a chimeric adenovirus vector expressing hemagglutinin and a double-stranded RNA adjuvant. Immunized ferrets and mice were protected upon lethal challenge. Further, ferrets immunized by the peroral route induced cross-clade neutralizing antibodies, and the antibodies were selective against hemagglutinin, not the vector. Similarly, experiments in mice demonstrated selective immune responses against HA with peroral delivery and the ability to circumvent preexisting vector immunity.

Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1

Vaccine ◽  
2016 ◽  
Vol 34 (41) ◽  
pp. 4875-4883 ◽  
Author(s):  
Tao Cheng ◽  
Xiang Wang ◽  
Yufeng Song ◽  
Xinying Tang ◽  
Chao Zhang ◽  
...  
Keyword(s):  
Avian Influenza ◽  
Influenza Vaccine ◽  
Adenovirus Vector ◽  
Lethal Challenge

scholarly journals CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge

2021 ◽  
Author(s):  
Chia-En Lien ◽  
Yi-Jiun Lin ◽  
Tsun-Yung Kuo ◽  
John D Campbell ◽  
Paula Traquina ◽  
...  
Keyword(s):  
Public Health ◽  
Neutralizing Antibodies ◽  
Rapid Development ◽  
Clinical Development ◽  
Spike Protein ◽  
Lung Pathology ◽  
Global Public Health ◽  
Control Groups ◽  
Virus Challenge ◽  
Igg Level

The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 μg or 5 μg of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 μg or 5 μg of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine.

Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs

Microbiology ◽  
2000 ◽  
Vol 81 (5) ◽  
pp. 1273-1281 ◽  
Author(s):  
Nora López ◽  
Luis Scolaro ◽  
Carlos Rossi ◽  
Rodrigo Jácamo ◽  
Nélida Candurra ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Guinea Pigs ◽  
Neutralizing Antibodies ◽  
Recombinant Vaccinia Virus ◽  
Glycoprotein Precursor ◽  
Lethal Challenge ◽  
Recombinant Vaccinia ◽  
Junin Virus ◽  
Virus Challenge ◽  
Junín Virus

Tacaribe virus (TACV) is an arenavirus that is genetically and antigenically closely related to Junin virus (JUNV), the aetiological agent of Argentine haemorrhagic fever (AHF). It is well established that TACV protects experimental animals fully against an otherwise lethal challenge with JUNV. To gain information on the nature of the antigens involved in cross-protection, recombinant vaccinia viruses were constructed that express the glycoprotein precursor (VV–GTac) or the nucleocapsid protein (VV–N) of TACV. TACV proteins expressed by vaccinia virus were indistinguishable from authentic virus proteins by gel electrophoresis. Guinea pigs inoculated with VV–GTac or VV–N elicited antibodies that immunoprecipitated authentic TACV proteins. Antibodies generated by VV–GTac neutralized TACV infectivity. Levels of antibodies after priming and boosting with recombinant vaccinia virus were comparable to those elicited in TACV infection. To evaluate the ability of recombinant vaccinia virus to protect against experimental AHF, guinea pigs were challenged with lethal doses of JUNV. Fifty per cent of the animals immunized with VV–GTac survived, whereas all animals inoculated with VV–N or vaccinia virus died. Having established that the heterologous glycoprotein protects against JUNV challenge, a recombinant vaccinia virus was constructed that expresses JUNV glycoprotein precursor (VV–GJun). The size and reactivity to monoclonal antibodies of the vaccinia virus-expressed and authentic JUNV glycoproteins were indistinguishable. Seventy-two per cent of the animals inoculated with two doses of VV–GJun survived lethal JUNV challenge. Protection with either VV–GJun or VV–GTac occurred in the presence of low or undetectable levels of neutralizing antibodies to JUNV.

scholarly journals Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-Term Sterilizing Immunity against Heterologous Challenge

2010 ◽  
Vol 84 (9) ◽  
pp. 4611-4618 ◽  
Author(s):  
Jennifer A. Schwartz ◽  
Linda Buonocore ◽  
Amorsolo L. Suguitan ◽  
Alex Silaghi ◽  
Darwyn Kobasa ◽  
...  
Keyword(s):  
Avian Influenza ◽  
Vesicular Stomatitis Virus ◽  
Neutralizing Antibodies ◽  
H5n1 Avian Influenza Virus ◽  
H5n1 Avian Influenza ◽  
Heterologous Challenge ◽  
Vesicular Stomatitis ◽  
Clade 1 ◽  
Pandemic Vaccine ◽  
Sterilizing Immunity

ABSTRACT The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (J. A. Schwartz et al., Virology 366:166-173, 2007). Here we have generated and characterized VSV-based vaccines that express the A/Hong Kong/156/1997 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Postchallenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.

Sign in / Sign up

Export Citation Format

Share Document